ScreenerHero

RLYBRallybio Corporation Common Stock

NAS · US · Healthcare · Biotechnology · rallybio.com
16.83USD-1.00%Mkt Cap: 89.38M $P/E: 2.11

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candida…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap89.38M $
Enterprise Value-4.69M $
Revenue (TTM)646.00K $
Gross Profit-16.54M $
Net Income (TTM)-8.98M $
Revenue/Share0.1140 USD
Last Price16.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.11
P/E (Forward)-3.07
PEG—
EV/EBITDA0.18
EV/Revenue-7.27
P/S136.46
P/B1.75
EPS (TTM)7.80
EPS (Forward)-5.40
52W Range
3.67095% of range17.57
52W High17.57 USD
52W Low3.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-3935.45%
EBITDA Margin0.00%
Profit Margin-1046.39%
ROE-15.49%
ROA-14.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.81M $
CapEx (TTM)—
FCF Margin-2212.13%
FCF Yield-15.99%
Net Debt-92.85M $
Net Debt/EBITDA3.66
Balance Sheet
Debt/Equity0.00
Current Ratio27.27
Quick Ratio26.03
Book Value/Sh9.504 USD
Cash/Share17.48 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.31M
Float2.18M
Insiders4.21%
Institutions229.87%
Short Interest
Short Ratio1.6d
Short % Float1.44%
Short % Out.1.20%
Shares Short63.48K
Short (prev mo.)408.75K
Technical
SMA 5016.16 (+4.1%)
SMA 20010.12 (+66.3%)
Beta-0.86
S&P 52W Chg18.16%
Avg Vol (30d)36.38K
Avg Vol (10d)20.98K
Technical Indicators
RSI (14)61.6
MACD0.2602
MACD Signal0.2090
MACD Hist.+0.0511
BB Upper17.16 USD
BB Middle16.39 USD
BB Lower15.62 USD
BB Width9.39%
ATR (14)0.4828 USD
Vol Ratio (20d)0.26x